UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...
French pharma major Sanofi today revealed it is shipping Beyfortus (nirsevimab-alip) 50mg and 100mg Injection doses in the ...
Investor's Business Daily on MSN6d
Moderna Crashes After Slashing Its R&D Budget, Issuing Light GuidanceModerna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget and issued a light sales view.
Sanofi is shipping BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection doses in the US to private healthcare providers and to the Centers for Disease Control and Prevention for its Vaccines for ...
Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.
THE LAWSUIT: A class action securities lawsuit was filed against Moderna, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 18, ...
The FDA’s clearance could double Kisqali’s breast cancer market. Elsewhere, Novo is exploring new ways to deliver genetic ...
THE LAWSUIT: A class action securities lawsuit was filed against Moderna, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between January 18, ...
Pfizer's complaint is that GSK and a Quebec, Canada-based subsidiary ID Biomedical are causing "commercial uncertainty" for its own RSV vaccine programme with the three patents, which Pfizer says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback